| Literature DB >> 27871292 |
Tatjana Sattler1,2, Jutta Pikalo3, Eveline Wodak3, Friedrich Schmoll3.
Abstract
BACKGROUND: In this study, six enzyme-linked immunosorbent assays (ELISA), intended for routine porcine reproductive and respiratory syndrome virus (PRRSV) herd monitoring, are tested for their ability to detect PRRSV specific antibodies in the serum of pigs after vaccination with an inactivated PRRSV type 1 vaccine and subsequent infection with a highly pathogenic (HP) PRRSV field strain. For this reason, ten piglets (group V) from a PRRSV negative herd were vaccinated twice at the age of 2 and 4 weeks with an inactivated PRRSV vaccine. Ten additional piglets (group N) from the same herd remained unvaccinated. Three weeks after second vaccination, each of the piglets received an intradermal application of an HP PRRSV field strain. Serum samples were taken before first vaccination as well as before and 3, 7, 10 and 14 days after HP PRRSV application. All serum samples were tested for PRRSV RNA by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) as well as for PRRSV antibodies with all six study ELISAs.Entities:
Keywords: ELISA; Inactivated vaccine; PRRSV; Swine
Mesh:
Substances:
Year: 2016 PMID: 27871292 PMCID: PMC5117522 DOI: 10.1186/s12917-016-0888-0
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Results of PRRSV Ab ELISAs at the sampling points, number of positive animals
| Study day | -33 | 0 | 3 | 7 | 10 | 14 |
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| Group V | ||||||
| IDEXX | 0 | 0b | 0b | 0b | 8a,b | 10a |
| INgezim | 0 | 9a | 7a | 10a | 10a | 10a |
| HIPRA A/S | 0 | 2b | 2b | 1b | 5b | 5b |
| HIPRA E/S | 0 | 0b | 0b | 0b | 2c | 2c |
| QIAGEN | 0 | 0b | 0b | 0b | 8a,b | 10a |
| AJ | 0 | 0b | 0b | 2b | 7a,b | 8a,b |
| Group N | ||||||
| IDEXX | 0 | 0 | 0 | 0 | 7b,c | 9a |
| INgezim | 0 | 1 | 0 | 0 | 10a,b | 10a |
| HIPRA A/S | 0 | 0 | 0 | 0 | 0c | 3b,c |
| HIPRA E/S | 0 | 0 | 0 | 0 | 0c | 0c |
| QIAGEN | 0 | 0 | 0 | 0 | 4c | 9a |
| AJ | 0 | 0 | 0 | 0 | 1c | 6a,b |
Group V: vaccination with an inactivated PRRSV type 1 vaccine on days -33 and -19
Groups V and N: intradermal application of an HP PRRSV field strain on day 0
Different letters indicate significant differences between the ELISAs in each group on each sampling point
Sensitivity (%) of PRRSV Ab ELISAs at each sampling point (95% confidence interval)
| Study day | 0 | 3 | 7 | 10 | 14 |
|---|---|---|---|---|---|
| Group V | |||||
| IDEXX | 0 (0–30) | 0 (0–30) | 0 (0–30) | 80 (44–98) | 100 (69–100) |
| INgezim | 90 (60–98) | 70 (35–93) | 100 (69–100) | 100 (69–100) | 100 (69–100) |
| HIPRA A/S | 20 (3–56) | 20 (3–56) | 10 (0–45) | 50 (19–81) | 50 (19–81) |
| HIPRA E/S | 0 (0–30) | 0 (0–30) | 0 (0–30) | 20 (3–56) | 20 (3–56) |
| QIAGEN | 0 (0–30) | 0 (0–30) | 0 (0–30) | 80 (44–98) | 100 (69–100) |
| AJ | 0 (0–30) | 0 (0–30) | 20 (3–56) | 70 (35–93) | 80 (44–98) |
| Group N | |||||
| IDEXX | n.d. | 0 (0–30) | 0 (0–30) | 70 (35–93) | 90 (60–98) |
| INgezim | n.d. | 0 (0–30) | 0 (0–30) | 100 (69–100) | 100 (69–100) |
| HIPRA A/S | n.d. | 0 (0–30) | 0 (0–30) | 0 (0–0) | 30 (7–65) |
| HIPRA E/S | n.d. | 0 (0–30) | 0 (0–30) | 0 (0–0) | 0 (0–0) |
| QIAGEN | n.d. | 0 (0–30) | 0 (0–30) | 40 (12–74) | 90 (60–98) |
| AJ | n.d. | 0 (0–30) | 0 (0–30) | 10 (0–45) | 60 (26–88) |
Group V: vaccination with an inactivated PRRSV type 1 vaccine on days -33 and -19
Groups V and N: intradermal application of an HP PRRSV field strain on day 0
n.d. not done
Fig. 1Boxplots of S/P values, respectively OD values of all tested PRRSV Ab ELISAs. Vaccinated group: vaccination with an inactivated PRRSV type 1 vaccine on days -33 and -19 (see arrows), both groups: intradermal application of an HP PRRSV field strain on day 0 (see arrows). Red lines: cut-off of the ELISAs. The black triangle indicates significant differences between the groups